[Asia Economy Reporter Minji Lee] Genome&Company announced on the 8th that it has received approval from the Ministry of Food and Drug Safety for the domestic Phase 2 clinical trial plan of the microbiome immuno-oncology drug GEN-001 targeting cholangiocarcinoma patients.
The company stated, "This is to secure safety and efficacy evaluation data of GEN-001 in combination with pembrolizumab for patients with progressive refractory cholangiocarcinoma."
▲NHN=Announced that operating profit for Q3 was 8.3 billion KRW, down 70% compared to the same period last year. Sales increased by 10% to 522.4 billion KRW.
▲Dongyang Life Insurance=Announced that operating profit for Q3 decreased by 49% to 67.3 billion KRW, and sales recorded 2.9827 trillion KRW, up 72.6% compared to the same period last year.
▲NHN Korea Cyber Payment=Announced that operating profit for Q3 was 13.1 billion KRW, up 18% compared to the same period last year. Sales increased by 8% to 209.7 billion KRW.
▲Genoray=Announced that operating profit for Q3 was 2 billion KRW, down 39% compared to the same period last year. Sales decreased by 3.6% to 16.5 billion KRW.
▲Ananti=Announced a turnaround to a profit with operating profit of 39.3 billion KRW for Q3. Sales increased by 130% to 90.8 billion KRW.
▲Cell Biotech=Announced that operating profit for Q3 was 2 billion KRW, down 31% compared to the same period last year. Sales decreased by 2.6% to 12.4 billion KRW.
▲Hi-Lok Korea=Announced that operating profit for Q3 was 10.2 billion KRW, up 54%. Sales grew by 23.5% to 43.4 billion KRW.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
